The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy

被引:0
|
作者
Liu, Tao [1 ]
Zhou, Ping [2 ]
Jiang, Xin [3 ]
Wang, Na [1 ]
Shou, Jialing [1 ]
Fang, Yuqiang [1 ,4 ]
机构
[1] Army Med Univ, Chongqing Inst Cardiol, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China
[2] First Peoples Hosp Chongqing Liang Jiang New Area, Dept Cardiol, Chongqing 401121, Peoples R China
[3] Peoples Hosp Chongqing Da Du Kou Area, Dept Cardiol, Chongqing, Peoples R China
[4] Army Med Univ, Dept Cardiol, Chongqing Inst Cardiol, Daping Hosp, 10 Changjiang Branch Rd, Chongqing 400042, Peoples R China
来源
JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2023年 / 28卷 / 01期
基金
中国国家自然科学基金;
关键词
Angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; beta-blockers; dilated cardiomyopathy; PREDICTORS; THERAPY; PREVALENCE; RECOVERY; INSIGHTS;
D O I
10.4103/jrms.jrms_626_21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD)<= 50 mm for females or <= 55 mm for males and left ventricular ejection fraction (LVEF) >= 45%; the criteria of "partial reversal" was the decreased rate of LVEDD (Delta LVEDD) >10% or the increase rate of LVEF (Delta LVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and Delta LVEDD <10%, and LVEF <45% and Delta LVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure
    Chitnis, Abhishek S.
    Aparasu, Rajender R.
    Chen, Hua
    Kunik, Mark E.
    Schulz, Paul E.
    Johnson, Michael L.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2016, 31 (05): : 395 - 404
  • [22] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review
    Úna C. Mc Menamin
    Liam J. Murray
    Marie M. Cantwell
    Carmel M. Hughes
    Cancer Causes & Control, 2012, 23 : 221 - 230
  • [23] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: A case for exclusion
    Bubbar, Carolyn D.
    Blackburn, David F.
    Wilson, Merne P.
    Wilson, Thomas W.
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (01) : 129 - 132
  • [24] Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers
    Walfisch, A.
    Al-maawali, A.
    Moretti, M. E.
    Nickel, C.
    Koren, G.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2011, 31 (06) : 465 - 472
  • [25] The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
    Sica, DA
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (02) : 66 - 71
  • [26] Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children
    Pedro Alves Soares Vaz de Castro
    Letícia Bitencourt
    Bruno Wilnes Simas Pereira
    Ananda Queiroz Rocha Lima
    Henrique Santos Hermida
    Carlos Roberto Moreira Neto
    Mariana Dinamarco Mestriner
    Ana Cristina Simões e Silva
    Pediatric Nephrology, 2022, 37 : 499 - 508
  • [27] Hyperkalemia of Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Hemodialysis: A Meta-analysis
    张茜
    栾弘
    王艻
    张妙
    陈艳
    吕永曼
    马祖福
    Current Medical Science, 2012, 32 (05) : 785 - 792
  • [28] Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: A meta-analysis
    Qian Zhang
    Hong Luan
    Le Wang
    Miao Zhang
    Yan Chen
    Yongman Lv
    Zufu Ma
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32 : 785 - 792
  • [29] The Potential Role of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Reducing Pneumonia Severity in Older Adults
    Thomas, Heledd
    Yoshimatsu, Yuki
    Thompson, Trevor
    Smithard, David G.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [30] Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer
    Helgeson, Scott A.
    Waddle, Mark R.
    Burnside, Rebecca C.
    Debella, Yalew T.
    Lee, Augustine S.
    Burger, Charles D.
    Li, Zhuo
    Johnson, Patrick W.
    Patel, Neal M.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (09) : 607 - 613